🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for DTC - Differentiated Thyroid Cancer

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer NCT05783323Phase 26 sites📍 San Francisco📍 Boston📍 Philadelphia Children's Hospital of Philadelphia · Tests: Larotrectinib monotherapy, 131I therapy Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer NCT06431620NA1 site📍 Nanjing Nanjing First Hospital, Nanjing Medical University · Tests: Recombinant Human Thyroid Stimulating Hormone Adjuvant Radiotherapy in High Risk Locally Advanced DTC NCT06558981Phase 31 site📍 Shanghai Fudan University · Tests: Radiotherapy, radioiodine treatment Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors NCT07545837NA1 site📍 Jacksonville Mayo Clinic · Tests: Counseling, Interview, Questionnaire Administration Sacituzumab govitEcan in THYroid Cancers NCT06235216Phase 211 sites📍 Barcelona📍 Ferrol📍 Hospitalet de Llobregat (Barcelona) Grupo Espanol de Tumores Neuroendocrinos · Tests: Sacituzumab govitecan Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) NCT06458036Phase 25 sites📍 San Francisco📍 Philadelphia📍 Memphis Children's Hospital of Philadelphia · Tests: Selpercatinib Monotherapy, 131I Therapy Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer NCT06898437EARLY Phase 11 site📍 Beijing Peking Union Medical College Hospital · Tests: 177Lu-LNC1004 Injection Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer NCT06970353Phase 21 site📍 Shanghai Fudan University · Tests: Tunlametinib, Tunlametinib+PD-1 mAb Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients NCT06853925NA1 site📍 Washington D.C. Georgetown University · Tests: Radioactive Iodine Support (RAI Support), Treatment as Usual (TAU) Pembrolizumab in High-risk Thyroid Cancer NCT05852223Phase 21 site📍 Pavia Istituti Clinici Scientifici Maugeri SpA · Tests: Pembrolizumab Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy NCT06671184n/a1 site📍 Shanghai Shanghai 6th People's Hospital · Tests: Observations on clinicopathological factors influencing the difficulty of surgery Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) NCT07092514Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Lenvatinib Lateral Cervical Node Dissection in Differentiated Thyroid Cancer. NCT06149637NA1 site📍 Medellín Centro de Excelencia en Enfermedades de Cabeza y Cuello · Tests: Traditional neck dissection approach, Anterior neck dissection approach Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer NCT06359847Phase 21 site📍 Beijing Beijing Scitech-Mq Pharmaceuticals Limited · Tests: ST-1898 tablets Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer NCT03099356Phase 21 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Cyclophosphamide, Sirolimus XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer NCT06959641Phase 22 sites📍 Torrance📍 Chicago Jochen Lorch · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration, X-Ray Imaging Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment NCT06405217NA1 site📍 Nanjing Nanjing First Hospital, Nanjing Medical University · Tests: Recombinant Human Thyroid Stimulating Hormone Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up NCT04290663Phase 329 sites📍 Pointe à Pitre📍 Angers📍 Angers Centre Francois Baclesse · Tests: Systematic RAI-treatment, Decision of RAI-treatment guided by a post-operative assessment A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer NCT07287748Phase 11 site📍 Kashiwa Alpha Fusion Inc. · Tests: [211At]NaAt F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer NCT07436455NA2 sites📍 Ankara📍 Ankara Ankara University · Tests: F-18-Tetrafluoroborate PET/CT Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer NCT06475989Phase 3307 sites📍 Anchorage📍 Anchorage📍 Anchorage ECOG-ACRIN Cancer Research Group · Tests: Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging Iodine Uptake After a Low Iodine Diet NCT05599139NA1 site📍 Groningen University Medical Center Groningen · Tests: Low iodine diet Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers NCT05604963NA33 sites📍 Crewe📍 Bath📍 Birmingham University College, London · Tests: Total Thyroidectomy, Hemithyroidectomy Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer NCT07777536Phase 21 site📍 Shanghai Fudan University · Tests: Selective coverage radiotherapy, comprehensive coverage radiotherapy The EMIRATES Study NCT06855680n/a1 site📍 Wigan Royal Marsden NHS Foundation Trust Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer NCT07068542NA1 site📍 Hangzhou Zhejiang Provincial People's Hospital · Tests: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264) Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer NCT06980103NA3 sites📍 Washington D.C.📍 Washington D.C.📍 Falls Church Georgetown University · Tests: Decision Aid, Usual Care Targeted Therapy to Increase RAI Uptake in Metastatic DTC NCT05024929n/a9 sites📍 San Francisco📍 Atlanta📍 Boston Children's Hospital of Philadelphia · Tests: Whole body scan The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer NCT03841617Phase 21 site📍 Bethesda National Institute of Diabetes and Digestive and Kidney Dis… · Tests: Thyrogen, I-131, I-124, Thyroid hormone withdrawal
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy